IMS 2022 | CARTITUDE-2 update: cilta-cel in relapsed and lenalidomide-refractory patients with multiple myeloma
Adam Cohen, MD, University of Pennsylvania, Philadelphia, PA, gives an update on the results of Cohort A from the CARTITUDE-2 trial (NCT04133636). Dr Cohen explains that in this patient population who has received 1-3 prior lines of treatment and is lenalidomide-refractory, ciltacabtagene autoleucel (cilta-cel) appeared to have promising durability and safety. The results of this study have led to the ongoing CARTITUDE-4 trial (NCT04181827) comparing cilta-cel vs standard triplet therapies in patients with relapsed and lenalidomide-refractory multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
